Christoph Reschreiter founded Cube Dx together with Bernhard Ronacher, after successfully developing and introducing hybcell technology to central European markets.
Altogether he has worked fifteen years in the diagnostics industry. Before his entrepreneurial endeavors he worked for the international B&R industry electronics group as the head of international customer projects department. He spent one year in Seoul (Republic of Korea) as an executive manager to set-up the newly founded Korean subsidiary.
Bernhard Ronacher is a molecular biologist, geneticist and biochemist. He had developed the basic idea of the hybcell and founded Cube Dx.
During the years 2000 to 2002 he headed the molecular diagnostics laboratory of Lambda GmbH. There he established the DNA array technology. 2001 the first Austrian biochip, ParoCheck, was filed for patent. Bernhard has now worked for almost twenty years in the development of advanced diagnostics solutions.
Cube Dx was founded in 2015 and is located in St. Valentin (Austria). The company focuses on the development, production and distribution of multiplex tests for in-vitro diagnostics in clinical routine. Multiplex diagnostics allow for the identification in parallel of a variety of significant parameters (bacteria, fungi, resistance markers, etc.) in a single test, requiring only a minimal amount of sample material.
Cube Dx entirely new multiplex technology - the hybcell – is the world's first cylindrical microarray – delivers speedy and reliable results with minimal effort. The hyborg – a completely automated device – processes the samples fully independently and without any intervention by the user. The Cube Dx assay is based on compact sequencing and is designed to address especially those complex diagnostic challenges where fast answers are essential.